Kolexia
Mathurin Philippe Gastro-entérologie
Mathurin Philippe
Gastro-entérologie
Hôpital Huriez
Lille, France
353 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hépatite Fibrose Cirrhose du foie Carcinome hépatocellulaire Maladies du foie Hépatite alcoolique Hépatite C Carcinomes Tumeurs du foie

Collaborateurs

Voir plus
Louvet Alexandre
Louvet Alexandre
Hôpital Huriez, Lille, France
Dharancy Sébastien
Dharancy Sébastien
Hôpital Huriez, Lille, France
Lassailly Guillaume
Lassailly Guillaume
Hôpital Huriez, Lille, France
De Ledinghen Victor
De Ledinghen Victor
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Ipsen
26 collaboration(s)
Dernière en 2023
Bayer
9 collaboration(s)
Dernière en 2023
Abbvie
8 collaboration(s)
Dernière en 2023
ADVANZ PHARMA FRANCE
5 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Essai Clinique (BMS)   15 mars 2024
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
Hepatology (Baltimore, Md.)   20 février 2024
Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis.
Alimentary pharmacology & therapeutics   01 février 2024
FRESH: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis
Essai Clinique (Intercept Pharmaceuticals)   26 janvier 2024
NATiV3: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Essai Clinique (Inventiva Pharma)   24 janvier 2024
Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
Clinics and research in hepatology and gastroenterology   13 décembre 2023
Conventional cytotoxic chemotherapy for gastrointestinal cancer in patients with cirrhosis: A multicentre case-control study.
Liver international : official journal of the International Association for the Study of the Liver   30 novembre 2023
Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Obesity (Silver Spring, Md.)   27 novembre 2023
Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
JHEP reports : innovation in hepatology   27 octobre 2023
REGENERATE: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Essai Clinique (Intercept Pharmaceuticals)   13 octobre 2023